107 related articles for article (PubMed ID: 20557848)
1. First-line treatment of patients with metastatic pancreatic cancer: results of a Phase II trial with S-1 (CESAR-Study group).
Strumberg D; Bergmann L; Graeven U; Hanauske A; Lipp R; Schuette J; Schultheis B; Scigalla P; Urrea P; Scheulen ME
Int J Clin Pharmacol Ther; 2010 Jul; 48(7):470-2. PubMed ID: 20557848
[No Abstract] [Full Text] [Related]
2. A late phase II study of S-1 for metastatic pancreatic cancer.
Okusaka T; Funakoshi A; Furuse J; Boku N; Yamao K; Ohkawa S; Saito H
Cancer Chemother Pharmacol; 2008 Apr; 61(4):615-21. PubMed ID: 17520253
[TBL] [Abstract][Full Text] [Related]
3. Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group).
Schultheis B; Strumberg D; Bergmann L; Graeven U; Hanauske AR; Lipp R; Schuette J; Saito K; Scigalla P; Scheulen ME
Invest New Drugs; 2012 Jun; 30(3):1184-92. PubMed ID: 21484249
[TBL] [Abstract][Full Text] [Related]
4. S-1 in the treatment of pancreatic cancer.
Sudo K; Nakamura K; Yamaguchi T
World J Gastroenterol; 2014 Nov; 20(41):15110-8. PubMed ID: 25386059
[TBL] [Abstract][Full Text] [Related]
5. A case of gemcitabine-refractory pancreatic cancer responsive to second-line chemotherapy using S-1.
Morizane C
Jpn J Clin Oncol; 2007 Dec; 37(12):973. PubMed ID: 18211987
[No Abstract] [Full Text] [Related]
6. An early phase II study of S-1 in patients with metastatic pancreatic cancer.
Ueno H; Okusaka T; Ikeda M; Takezako Y; Morizane C
Oncology; 2005; 68(2-3):171-8. PubMed ID: 16006754
[TBL] [Abstract][Full Text] [Related]
7. High response rates in patients with pancreatic cancer using the novel oral fluoropyrimidine S-1.
Hayashi K; Imaizumi T; Uchida K; Kuramochi H; Takasaki K
Oncol Rep; 2002; 9(6):1355-61. PubMed ID: 12375048
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for resected pancreatic cancer.
Aoyama T; Katayama Y; Murakawa M; Asari M; Kanazawa A; Higuchi A; Shiozawa M; Kobayashi S; Ueno M; Morimoto M; Ohkawa S; Akaike M; Yamamoto N; Yoshikawa T; Rino Y; Masuda M; Morinaga S
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1235-40. PubMed ID: 25297990
[TBL] [Abstract][Full Text] [Related]
9. Randomized Phase II Study of Consecutive-Day versus Alternate-Day Treatment with S-1 as Second-Line Chemotherapy in Advanced Pancreatic Cancer.
Ishikawa T; Kawashima H; Ohno E; Matsubara H; Sasaki Y; Achiwa K; Kanamori A; Sumi H; Hirai T; Nonogaki K; Tsuzuki T; Kuroiwa M; Hattori M; Maruta S; Hiramatsu T; Ando M; Hashimoto S; Hirooka Y
Oncology; 2019; 96(1):1-7. PubMed ID: 30368509
[TBL] [Abstract][Full Text] [Related]
10. Letter to the editor: "Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer".
Molina-Garrido MJ; Guillén-Ponce C
Invest New Drugs; 2011 Dec; 29(6):1515-6. PubMed ID: 21161325
[No Abstract] [Full Text] [Related]
11. The role of S-1 in the treatment of gastric cancer.
Kubota T
Br J Cancer; 2008 Apr; 98(8):1301-4. PubMed ID: 18362933
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial.
Shiroiwa T; Fukuda T; Shimozuma K; Mouri M; Hagiwara Y; Kawahara T; Ohsumi S; Hozumi Y; Sagara Y; Ohashi Y; Mukai H
BMC Cancer; 2017 Nov; 17(1):773. PubMed ID: 29149882
[TBL] [Abstract][Full Text] [Related]
13. Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer.
Yamaue H; Shimizu A; Hagiwara Y; Sho M; Yanagimoto H; Nakamori S; Ueno H; Ishii H; Kitano M; Sugimori K; Maguchi H; Ohkawa S; Imaoka H; Hashimoto D; Ueda K; Nebiki H; Nagakawa T; Isayama H; Yokota I; Ohashi Y; Shirasaka T
Cancer Chemother Pharmacol; 2017 Apr; 79(4):813-823. PubMed ID: 28251282
[TBL] [Abstract][Full Text] [Related]
14. S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure.
Todaka A; Fukutomi A; Boku N; Onozawa Y; Hironaka S; Yasui H; Yamazaki K; Taku K; Machida N; Sakamoto T; Tomita H
Jpn J Clin Oncol; 2010 Jun; 40(6):567-72. PubMed ID: 20189975
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of stereotactic body radiation therapy combined with S-1 simultaneously followed by sequential S-1 as an initial treatment for locally advanced pancreatic cancer (SILAPANC) trial: study design and rationale of a phase II clinical trial.
Zhu X; Ju X; Cao F; Fang F; Qing S; Shen Y; Jia Z; Cao Y; Zhang H
BMJ Open; 2016 Dec; 6(12):e013220. PubMed ID: 27909037
[TBL] [Abstract][Full Text] [Related]
16. [Low-dose mirtazapine improved nausea and appetite loss during S-1 therapy].
Shibahara H; Ito T; Uematsu N; Imai E; Nishimura D
Gan To Kagaku Ryoho; 2012 Jan; 39(1):143-5. PubMed ID: 22241371
[TBL] [Abstract][Full Text] [Related]
17. [Curatively resected case of non-functioning pancreatic neuroendocrine carcinoma with multiple liver metastases after downstaging with S-1 monotherapy].
Sato I; Ueda N; Kinoshita E; Minato H; Ohno K; Nakaya N; Shimasaki T; Nakajima H; Kosaka T; Motoo Y
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1341-4. PubMed ID: 20647723
[TBL] [Abstract][Full Text] [Related]
18. Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer.
Yamaue H; Satoi S; Kanbe T; Miyazawa M; Tani M; Kawai M; Hirono S; Okada K; Yanagimoto H; Kwon AH; Mukouyama T; Tsunoda H; Chijiiwa K; Ohuchida J; Kato J; Ueda K; Yamaguchi T; Egawa S; Hayashi K; Shirasaka T
Cancer Chemother Pharmacol; 2014 Jan; 73(1):97-102. PubMed ID: 24146260
[TBL] [Abstract][Full Text] [Related]
19. [Corneal epithelial disorder, lacrimal drainage obstruction, and conjunctivitis].
Kase S
Nihon Rinsho; 2015 Feb; 73 Suppl 2():490-3. PubMed ID: 25831809
[No Abstract] [Full Text] [Related]
20. Effect of S-1 on survival outcomes in 838 patients with advanced pancreatic cancer: A 7-year multicenter observational cohort study in Taiwan.
Lai HL; Chen YY; Lu CH; Hung CY; Kuo YC; Chen JS; Hsu HC; Chen PT; Chang PH; Hung YS; Chou WC
Cancer Med; 2019 May; 8(5):2085-2094. PubMed ID: 31001907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
